The right to health in the jurisprudence of European Court of Human Rights and Inter-American Court of Human Rights

El derecho a la salud es garantizado en múltiples instrumentos jurídicos internacionales de manera directa e indirecta. Sin perjuicio del marco general que configura la Carta de Derechos Humanos, los sistemas de protección de la OEA y del Consejo de Europa se ocupan cuidadosamente de velar por la máxima protección individual y colectiva de la salud. En los últimos años, la Corte Interamericana de Derechos Humanos, amparándose principalmente en la Convención Americana sobre Derechos Humanos, ha condenado la violación del derecho a la salud en numerosas ocasiones y en relación a casos recientes. Del mismo modo, el Tribunal Europeo de Derechos Humanos, de conformidad con el artículo 8.2 y otros derechos vinculados a este precepto, vela porque los Estados protejan a sus ciudadanos y les presten el nivel más elevado y adecuado de salud.The right to health is guaranteed in multiple international legal instruments directly and indirectly. Although the Charter of Human Rights provides a system of general protection, the systems of the OAS and the Council of Europe are carefully engaged to ensure the maximum individual and collective protection of health. The Inter-American Court of Human Rights, under the umbrella of the American Convention on Human Rights, has condemned the violation of the right to health on numerous occasions, in recent years, a regarding fresh and recent cases. In the same way, the European Court of Human Rights, in accordance with Article 8.2 and other associated rights, ensures that States protect their citizens and provide them with the highest attainable standard of health.Proyecto I+D Excelencia 2015 DER2015- 65906-PProyecto I+D+i Europa Investigación EUIN2017-8543

Biological experiments with human beings in the framework of armed conflict law

En situaciones de conflicto armado, los Convenios de Ginebra prohíben la práctica de experimentos biológicos o científicos, excepto cuando estén justificados médicamente. En este sentido, los principios éticos y jurídicos de asistencia a la salud continúan rigiendo las actuaciones del personal de salud, quienes ostentan siempre el deber de proteger la salud física y mental de las personas, así como el de aliviar su sufrimiento, de conformidad con el derecho.In situations of armed conflict, the Geneva Conventions prohibit the practice of biological or scientific experiments, except when they are medically justified. In this sense, the ethical and legal principles of health care continue to govern the actions of health personnel, who always have the duty to protect the physical and mental health of people and alleviate their suffering in accordance with the right.Unión Europea EUIN2017-8543

The impact of the COVID-19 pandemic in diabetes and dyslipidemia management in a Spanish region: a retrospective study of the Aragon population

IntroductionPrevious research has indicated that the COVID-19 outbreak had a negative impact on the diagnosis and management of cardiometabolic diseases. Our aim was to analyze the impact of the COVID-19 pandemic on the management of dyslipidemia and type 2 diabetes (T2D) in the Aragon region of Spain.MethodsWe conducted an observational retrospective study, which included data from all patients diagnosed with active T2D or dyslipidemia in Aragon during 2019–2021. Data was collected from the BIGAN platform, a big database that includes all healthcare data from the Aragon population. Clinical, biochemical, and pharmacological prescription information was obtained for each patient and for each year.ResultsOut of the total population of 1,330,000 in the Aragon region, 90,000 subjects were diagnosed with T2D each year, resulting in a prevalence of approximately 7%. The COVID-19 pandemic resulted in a decrease in the prevalence of this disease and a lower incidence during the year 2020. In addition, patients with T2D experienced a deterioration of their glucose profile, which led to an increase in the number of patients requiring pharmacological therapy. The prevalence of dyslipidemia was approximately 23.5% in both 2019 and 2020 and increased to 24.5% in 2021. Despite the worsening of the anthropometric profile, the lipid profile improved significantly throughout 2020 and 2021 compared to 2019. Moreover, the number of active pharmacological prescriptions increased significantly in 2021.DiscussionOur findings suggest that the overload of the health system caused by the COVID-19 pandemic has resulted in an underdiagnosis of T2D. Moreover, patients with T2D experienced a worsening of their glycemic profile, an increase in their pharmacological requirements, and lower performance of their analytical determinations. Dyslipidemic subjects improved their lipid profile although the value of lipid profile determination decreased between 2020 and 2021

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected by RNA-Seq in tumor samples from 139 newly diagnosed glioblastoma patients to identify in-frame fusions with predictable oncogenic potential. Among 61 samples with fusions, there were 103 different fusions, involving 167 different genes, including 20 known oncogenes or tumor suppressor genes (TSGs), 16 associated with cancer but not oncogenes or TSGs, and 32 not associated with cancer but previously shown to be involved in fusions in gliomas. After selecting in-frame fusions able to produce a protein product and running Oncofuse, we identified 30 fusions with predictable oncogenic potential and classified them into four non-overlapping categories: six previously described in cancer; six involving an oncogene or TSG; four predicted by Oncofuse to have oncogenic potential; and 14 other in-frame fusions. Only 24 patients harbored one or more of these 30 fusions, and only two fusions were present in more than one patient: FGFR3::TACC3 and EGFR::SEPTIN14. This in silico study provides a good starting point for the identification of gene fusions with functional consequences in the pathogenesis or treatment of glioblastoma

Objetivos de desarrollo sostenible y Derechos Humanos: paz, justicia e instituciones sólidas / Derechos Humanos y empresas

Nota previa / Cástor Miguel Díaz Barrado (pp. 7-9). -- Unión Europea: Derechos Humanos y desarrollo sostenible / Araceli Mangas Martín (pp. 13 - 26). -- Paz, seguridad y gobernanza: el ODS 16 y la Agenda 2030 de desarrollo sostenible / José Antonio Sanahuja (pp. 27 - 54). -- La aplicación extraterritorial de los Derechos Humanos por acciones de empresas / Pablo Antonio Fernández Sánchez (pp. 57 - 60). -- Hacia un futuro tratado internacional sobre las empresas y los Derechos Humanos / Eugenia López-Jacoiste (pp. 61 - 73). -- La importancia del enfoque de los Derechos Humanos en los objetivos de desarrollo del sostenible / Diana M. Verdiales López (pp. 75 - 90). -- La perspectiva de género en la resolución de conflictos armados: las mujeres como agentes de paz / Cristina del Prado Higuera (pp. 93 - 106). -- La mutilación genital femenina desde una perspectiva integral y multidisciplinar / Cristina Hermida del Llano (pp. 107 - 120). -- Poner fin al maltrato, la explotación, la trata y todas las formas de violencia y tortura contra los niños: la trata de niños / María Ángeles Cano Linares (pp. 123 - 136). -- Participación juvenil en el fortalecimiento de las instituciones y el establecimiento de la paz: programas de participación juvenil del sistema de Naciones Unidas / Enrique Hernández Díez (pp. 137 - 160). -- Estado de la violencia criminal en la sociedad internacional: respuestas de la comunidad internacional para avanzar hacia el objetivo 16, Agenda 2030 / Sagrario Morán Blanco (pp. 163 - 178). -- Fortalecer la recuperación y devolución de bienes robados: justicia y reparación del daño causado a las víctimas y la sociedad como metas del objetivo 16 de los objetivos de desarrollo sostenible / Francisco Jiménez García (pp. 179 - 192). -- El derecho internacional, los ODS y la lucha contra el crimen transnacional / Juan Manuel Rodríguez Barrigón (pp. 193 - 216). -- El derecho internacional frente a la criminalidad financiera transnacional: la prevención y sanción del blanqueo de capitales / Jorge Urbaneja Cillán (pp. 217 - 232). -- Acceso a la justicia y objetivos del desarrollo sostenible / Florabel Quispe Remón (pp. 235 - 248). -- Paz y objetivos de desarrollo sostenible: la contribución del objetivo 16 / Elena C. Díaz Galán (pp. 249 - 262). -- Seguridad sanitaria y empresas / Ana Cristina Gallego Hernández (pp. 265 - 272). -- El acaparamiento de tierras por empresas multinacionales y la seguridad alimentaria / Adriana Fillol Mazo (pp. 273 - 288). -- Importancia y características de los planes nacionales de empresas y Derechos Humanos en relación con el desarrollo sostenible / Alberto Jiménez-Piernas García (pp. 289 - 301). -- Objetivo de desarrollo sostenible 16. Principios rectores y espacio iberoamericano: el caso Berta Cáceres / Ana Manero Salvador (pp. 305 - 315). -- Derechos de los pueblos indígenas: marcos de protección en la Agenda 2030 y en los principios rectores sobre empresas y Derechos Humanos / Juan Daniel Oliva Martínez y Adriana Sánchez Lizama (pp. 317 - 331

Manejo de la inmunosupresión en pacientes trasplantados de riñón con COVID19. Estudio multicéntrico nacional derivado del registro COVID de la Sociedad Española de Nefrología

Introduction: SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the management of the infection in the absence of targeted antiviral treatment. This has been modified according to the patient`s clinical situation and its effect on renal function or anti-HLA antibodies in the medium term has not been evaluated.Objectives: Evaluate the management of immunosuppressive therapy made during SARS-CoV2 infection, as well as renal function and anti-HLA antibodies in kidney transplant patients 6 months after COVID19 diagnosis.Material and methods: Retrospective, national multicentre, retrospective study (30 centres) of kidney transplant recipients with COVID19 from 01/02/20 to 31/12/20. Clinical variables were collected from medical records and included in an anonymised database. SPSS statistical software was used for data analysis.Results: renal transplant recipients with COVID19 were included (62.6% male), with a mean age of 57.5 years. The predominant immunosuppressive treatment prior to COVID19 was triple therapy with prednisone, tacrolimus and mycophenolic acid (54.6%) followed by m-TOR inhibitor regimens (18.6%). After diagnosis of infection, mycophenolic acid was discontinued in 73.8% of patients, m-TOR inhibitor in 41.4%, tacrolimus in 10.5% and cyclosporin A in 10%. In turn, 26.9% received dexamethasone and 50.9% were started on or had their baseline prednisone dose increased. Mean creatinine before diagnosis of COVID19, at diagnosis and at 6 months was: 1.7 +/- 0.8, 2.1 +/- 1.2 and 1.8 +/- 1 mg/dl respectively (p < 0.001). 56.9% of the patients (N = 350) were monitored for anti-HLA antibodies. 94% (N = 329) had no anti-HLA changes, while 6% (N = 21) had positive anti-HLA antibodies. Among the patients with donor-specific antibodies post-COVID19 (N = 9), 7 patients (3.1%) had one immunosuppressant discontinued (5 patients had mycophenolic acid and 2 had tacrolimus), 1 patient had both immunosuppressants discontinued (3.4%) and 1 patient had no change in immunosuppression (1.1%), these differences were not significant.Conclusions: The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis

Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases : multicentre study of 80 patients

Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs

Fuentes orales y archivos: Modelos de Syllabus de clases prácticas para Grados de Historia, Historia del Arte y Arqueología

Este documento contiene la memoria final del proyecto de innovación docente nº. 11 de la convocatoria para el curso académico 2022-2023. En ella se contiene modelos de clases prácticas para aquellos profesores de los Grados de Historia, Historia del Arte o Arqueología que pudieran impartir asignaturas de dichos Grados.Depto. de Historia Moderna y ContemporáneaFac. de Geografía e HistoriaFALSEsubmitte

Bronchoscopist's perception of the quality of the single-use bronchoscope (Ambu aScope4™) in selected bronchoscopies: a multicenter study in 21 Spanish pulmonology services

Background: The disposable bronchoscope is an excellent alternative to face the problem of SARS-CoV-2 and other cross infections, but the bronchoscopist’s perception of its quality has not been evaluated. Methods: To evaluate the quality of the Ambu-aScope4 disposable bronchoscope, we carried out a cross-sectional study in 21 Spanish pulmonology services. We use a standardized questionnaire completed by the bronchoscopists at the end of each bronchoscopy. The variables were described with absolute and relative frequencies, measures of cen‑ tral tendency and dispersion depending on their nature. The existence of learning curves was evaluated by CUSUM analysis. Results: The most frequent indications in 300 included bronchoscopies was bronchial aspiration in 69.3% and the median duration of these was 9.1 min. The route of entry was nasal in 47.2% and oral in 34.1%. The average score for ease of use, image, and aspiration quality was 80/100. All the planned techniques were performed in 94.9% and the bronchoscopist was satisfed in 96.6% of the bronchoscopies. They highlighted the portability and immediacy of the aScope4TM to start the procedure in 99.3%, the possibility of taking and storing images in 99.3%. The CUSUM analysis showed average scores>70/100 from the frst procedure and from the 9th procedure more than 80% of the scores exceeded the 80/100 score